HER-2/neu immunoreactivity in invasive mammary carcinomas: a comparative study using monoclonal and polyclonal antibodies including the HercepTestTM
Autor(a) principal: | |
---|---|
Data de Publicação: | 2004 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Jornal Brasileiro de Patologia e Medicina Laboratorial (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1676-24442004000100008 |
Resumo: | INTRODUCTION: HER-2/neu overexpression has been tested using immunohistochemistry as a reliable and cost-effective method to select patients with invasive mammary carcinomas (IMC) for trastuzumab treatment, but there is no consensus regarding the best antibody to be used. The aim of the present study was to test five different antibodies for determining the status of HER-2/neu overexpression in IMC. MATERIAL AND METHODS: Sixty-six formalin-fixed, paraffin-embedded IMC were investigated by immunohistochemistry, using two polyclonal antibodies, HercepTestTM (Dako) and A0485 (Dako), and three monoclonal antibodies, the clone CB11, from both Novocastra Laboratories and from Biogenex, and the clone 4D5 (Genentech). All immunostainings were scored according to the guidelines for the HercepTestTM. RESULTS: The A0485 was positive in 25 cases (37.9%). The HercepTestTM was positive in 14/66 cases (21.2%). Both CB11 antibodies yielded a positive reaction in the same nine patients (13.6%). The 4D5 was positive in only 4/66 cases (6.1%). All positive cases for CB11 or 4D5 were HercepTestTMpositive. All cases positive for HercepTestTM were positive for A0485. Most of the HercepTestTM and A0485 2+ cases were negative when using the other antibodies. DISCUSSION: There was a higher number of cases presenting HER-2/neu positivity with the A0485 and HercepTestTM than with the other antibodies, primarily in cases scored as 2+. There was no difference in positivity when the CB11Ab was used, regardless of company. CONCLUSION: The use of immunohistochemistry for the clinical assessment of HER-2/neu overexpression still needs prospective validation. |
id |
SBP-1_6c0dec4838e0e6b68b926ab46b114966 |
---|---|
oai_identifier_str |
oai:scielo:S1676-24442004000100008 |
network_acronym_str |
SBP-1 |
network_name_str |
Jornal Brasileiro de Patologia e Medicina Laboratorial (Online) |
repository_id_str |
|
spelling |
HER-2/neu immunoreactivity in invasive mammary carcinomas: a comparative study using monoclonal and polyclonal antibodies including the HercepTestTMBreast cancerHER-2/neuc-erbB-2ImmunohistochemistryPathologyINTRODUCTION: HER-2/neu overexpression has been tested using immunohistochemistry as a reliable and cost-effective method to select patients with invasive mammary carcinomas (IMC) for trastuzumab treatment, but there is no consensus regarding the best antibody to be used. The aim of the present study was to test five different antibodies for determining the status of HER-2/neu overexpression in IMC. MATERIAL AND METHODS: Sixty-six formalin-fixed, paraffin-embedded IMC were investigated by immunohistochemistry, using two polyclonal antibodies, HercepTestTM (Dako) and A0485 (Dako), and three monoclonal antibodies, the clone CB11, from both Novocastra Laboratories and from Biogenex, and the clone 4D5 (Genentech). All immunostainings were scored according to the guidelines for the HercepTestTM. RESULTS: The A0485 was positive in 25 cases (37.9%). The HercepTestTM was positive in 14/66 cases (21.2%). Both CB11 antibodies yielded a positive reaction in the same nine patients (13.6%). The 4D5 was positive in only 4/66 cases (6.1%). All positive cases for CB11 or 4D5 were HercepTestTMpositive. All cases positive for HercepTestTM were positive for A0485. Most of the HercepTestTM and A0485 2+ cases were negative when using the other antibodies. DISCUSSION: There was a higher number of cases presenting HER-2/neu positivity with the A0485 and HercepTestTM than with the other antibodies, primarily in cases scored as 2+. There was no difference in positivity when the CB11Ab was used, regardless of company. CONCLUSION: The use of immunohistochemistry for the clinical assessment of HER-2/neu overexpression still needs prospective validation.Sociedade Brasileira de Patologia Clínica2004-02-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1676-24442004000100008Jornal Brasileiro de Patologia e Medicina Laboratorial v.40 n.1 2004reponame:Jornal Brasileiro de Patologia e Medicina Laboratorial (Online)instname:Sociedade Brasileira de Patologia (SBP)instacron:SBP10.1590/S1676-24442004000100008info:eu-repo/semantics/openAccessGouvêa,Agostinho PintoFernandes,José Roberto MaggiOlson,Sandra JeanBrandão,Eduardo de CarvalhoLeite,Miguel TorresGobbi,Heleniceeng2004-06-08T00:00:00Zoai:scielo:S1676-24442004000100008Revistahttp://www.scielo.br/jbpmlhttps://old.scielo.br/oai/scielo-oai.php||jbpml@sbpc.org.br1678-47741676-2444opendoar:2004-06-08T00:00Jornal Brasileiro de Patologia e Medicina Laboratorial (Online) - Sociedade Brasileira de Patologia (SBP)false |
dc.title.none.fl_str_mv |
HER-2/neu immunoreactivity in invasive mammary carcinomas: a comparative study using monoclonal and polyclonal antibodies including the HercepTestTM |
title |
HER-2/neu immunoreactivity in invasive mammary carcinomas: a comparative study using monoclonal and polyclonal antibodies including the HercepTestTM |
spellingShingle |
HER-2/neu immunoreactivity in invasive mammary carcinomas: a comparative study using monoclonal and polyclonal antibodies including the HercepTestTM Gouvêa,Agostinho Pinto Breast cancer HER-2/neu c-erbB-2 Immunohistochemistry Pathology |
title_short |
HER-2/neu immunoreactivity in invasive mammary carcinomas: a comparative study using monoclonal and polyclonal antibodies including the HercepTestTM |
title_full |
HER-2/neu immunoreactivity in invasive mammary carcinomas: a comparative study using monoclonal and polyclonal antibodies including the HercepTestTM |
title_fullStr |
HER-2/neu immunoreactivity in invasive mammary carcinomas: a comparative study using monoclonal and polyclonal antibodies including the HercepTestTM |
title_full_unstemmed |
HER-2/neu immunoreactivity in invasive mammary carcinomas: a comparative study using monoclonal and polyclonal antibodies including the HercepTestTM |
title_sort |
HER-2/neu immunoreactivity in invasive mammary carcinomas: a comparative study using monoclonal and polyclonal antibodies including the HercepTestTM |
author |
Gouvêa,Agostinho Pinto |
author_facet |
Gouvêa,Agostinho Pinto Fernandes,José Roberto Maggi Olson,Sandra Jean Brandão,Eduardo de Carvalho Leite,Miguel Torres Gobbi,Helenice |
author_role |
author |
author2 |
Fernandes,José Roberto Maggi Olson,Sandra Jean Brandão,Eduardo de Carvalho Leite,Miguel Torres Gobbi,Helenice |
author2_role |
author author author author author |
dc.contributor.author.fl_str_mv |
Gouvêa,Agostinho Pinto Fernandes,José Roberto Maggi Olson,Sandra Jean Brandão,Eduardo de Carvalho Leite,Miguel Torres Gobbi,Helenice |
dc.subject.por.fl_str_mv |
Breast cancer HER-2/neu c-erbB-2 Immunohistochemistry Pathology |
topic |
Breast cancer HER-2/neu c-erbB-2 Immunohistochemistry Pathology |
description |
INTRODUCTION: HER-2/neu overexpression has been tested using immunohistochemistry as a reliable and cost-effective method to select patients with invasive mammary carcinomas (IMC) for trastuzumab treatment, but there is no consensus regarding the best antibody to be used. The aim of the present study was to test five different antibodies for determining the status of HER-2/neu overexpression in IMC. MATERIAL AND METHODS: Sixty-six formalin-fixed, paraffin-embedded IMC were investigated by immunohistochemistry, using two polyclonal antibodies, HercepTestTM (Dako) and A0485 (Dako), and three monoclonal antibodies, the clone CB11, from both Novocastra Laboratories and from Biogenex, and the clone 4D5 (Genentech). All immunostainings were scored according to the guidelines for the HercepTestTM. RESULTS: The A0485 was positive in 25 cases (37.9%). The HercepTestTM was positive in 14/66 cases (21.2%). Both CB11 antibodies yielded a positive reaction in the same nine patients (13.6%). The 4D5 was positive in only 4/66 cases (6.1%). All positive cases for CB11 or 4D5 were HercepTestTMpositive. All cases positive for HercepTestTM were positive for A0485. Most of the HercepTestTM and A0485 2+ cases were negative when using the other antibodies. DISCUSSION: There was a higher number of cases presenting HER-2/neu positivity with the A0485 and HercepTestTM than with the other antibodies, primarily in cases scored as 2+. There was no difference in positivity when the CB11Ab was used, regardless of company. CONCLUSION: The use of immunohistochemistry for the clinical assessment of HER-2/neu overexpression still needs prospective validation. |
publishDate |
2004 |
dc.date.none.fl_str_mv |
2004-02-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1676-24442004000100008 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1676-24442004000100008 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/S1676-24442004000100008 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Sociedade Brasileira de Patologia Clínica |
publisher.none.fl_str_mv |
Sociedade Brasileira de Patologia Clínica |
dc.source.none.fl_str_mv |
Jornal Brasileiro de Patologia e Medicina Laboratorial v.40 n.1 2004 reponame:Jornal Brasileiro de Patologia e Medicina Laboratorial (Online) instname:Sociedade Brasileira de Patologia (SBP) instacron:SBP |
instname_str |
Sociedade Brasileira de Patologia (SBP) |
instacron_str |
SBP |
institution |
SBP |
reponame_str |
Jornal Brasileiro de Patologia e Medicina Laboratorial (Online) |
collection |
Jornal Brasileiro de Patologia e Medicina Laboratorial (Online) |
repository.name.fl_str_mv |
Jornal Brasileiro de Patologia e Medicina Laboratorial (Online) - Sociedade Brasileira de Patologia (SBP) |
repository.mail.fl_str_mv |
||jbpml@sbpc.org.br |
_version_ |
1752122293550579712 |